logo
logo

Viaqua Therapeutics Announces $4.3 Million Investment Led By S2G Ventures For Its Rna-Based Aquaculture Health Platform

Jun 09, 2021•about 4 years ago

Amount Raised

$4.3 Million

Round Type

seed

Description

ViAqua Therapeutics, a biotechnology company and developer of an orally administered RNA-particle platform to promote and improve animal health in aquaculture, announced it has completed a $4.3 million round to commercialize and expand its platform. Multinational new investors include: S2G Ventures (S2G Oceans & Seafood Fund), Thai Union, and Agriline. Earlier investors Nutreco, Visvires New Protein, The Trendlines Group (SGX:42:T;OTCQX: TRNLY) and the Technion Israel Institute of Technology also participated in this round. ViAqua was also awarded additional grant funding from the Israeli Innovation Authority.

Company Information

Company

Vi Aqua Therapeutics

About

ViAqua was established to address the growing need for effective, specific, and affordable health management of diseases in aquaculture. One of the major challenges facing the shift to sustainable aquaculture practice is the prevention and treatment of disease. ViAqua is developing a biotechnology-based, oral delivery platform for administration of nucleic acid-based solutions for promoting health in marine species. Contact information:Shai Ufaz, Co-founder and CEO, ViAqua Therapeutics[email protected]+972.528430591 SOURCE ViAqua Therapeutics

FundzWatch™ Score

70
Medium Activity

Buyer Intent Analysis

Get personalized insights on buying likelihood